TargetBeta
CD40LG
CD40 ligand · also CD40L, TRAP, gp39, hCD40L · CD molecules
7 programs in company-led studies act on CD40LG, from 7 companies: 4 in phase 3. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (6 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| frexalimab | Sanofi | phase 3 | 119 running | – | the company's pipeline |
| dapirolizumab pegolrule | UCB | phase 3 | 83 running | – | ChEMBL |
| tegoprubartrule | Eledon Pharmaceuticals | phase 3 | 83 running | – | ChEMBL |
| dazodalibeprule | Amgen | phase 3 | 92 running | – | ChEMBL |
| OPT101rule | Op-T | phase 2 | 42 running | – | the studies' text |
| ravagalimabrule | AbbVie | phase 2 | 41 running | – | ChEMBL |
| TNX-1500rule | Tonix Pharmaceuticals | phase 1 | 10 running | – | the studies' text |
Conditions their studies are in
- Diabetes Mellitus, Type 1, 3 programs
- Sjogren's Syndrome, 3 programs
- Arthritis, Rheumatoid, 2 programs
- Lupus Erythematosus, Systemic, 2 programs
- Amyotrophic Lateral Sclerosis, 1 program
- Colitis, Ulcerative, 1 program
- Glomerulonephritis, IGA, 1 program
- Glomerulosclerosis, Focal Segmental, 1 program
- Kidney Failure, Chronic, 1 program
- Multiple Sclerosis, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Dec 23, 2026frexalimab · Sanofi · phase 3 · NCT06500702
- Jan 2027tegoprubart · Eledon Pharmaceuticals · phase 3 · NCT05027906
- Feb 2027ravagalimab · AbbVie · phase 2 · NCT06972446
- May 31, 2027OPT101 · Op-T · phase 2 · NCT06964087
- May 31, 2028dapirolizumab pegol · UCB · phase 3 · NCT06617325
- Dec 11, 2029dazodalibep · Amgen · phase 3 · NCT06747949
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.